Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 1;28(7):1560-1568.
doi: 10.1093/annonc/mdx152.

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials

R Yerushalmi  1 , B Dong  2 , J W Chapman  2 , P E Goss  3 , M N Pollak  4 , M J Burnell  5 , M N Levine  6 , V H C Bramwell  7 , K I Pritchard  8 , T J Whelan  9 , J N Ingle  10 , L E Shepherd  2 , W R Parulekar  2 , L Han  2 , K Ding  2 , K A Gelmon  11
Affiliations

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials

R Yerushalmi et al. Ann Oncol. .

Abstract

Background: We hypothesized that increased baseline BMI and BMI change would negatively impact clinical outcomes with adjuvant breast cancer systemic therapy.

Methods: Data from chemotherapy trials MA.5 and MA.21; endocrine therapy MA.12, MA.14 and MA.27; and trastuzumab HERA/MA.24 were analyzed. The primary objective was to examine the effect of BMI change on breast cancer-free interval (BCFI) landmarked at 5 years; secondary objectives included BMI changes at 1 and 3 years; BMI changes on disease-specific survival (DSS) and overall survival (OS); and effects of baseline BMI. Stratified analyses included trial therapy and composite trial stratification factors.

Results: In pre-/peri-/early post-menopausal chemotherapy trials (N = 2793), baseline BMI did not impact any endpoint and increased BMI from baseline did not significantly affect BCFI (P = 0.85) after 5 years although it was associated with worse BCFI (P = 0.03) and DSS (P = 0.07) after 1 year. BMI increase by 3 and 5 years was associated with better DSS (P = 0.01; 0.01) and OS (P = 0.003; 0.05). In pre-menopausal endocrine therapy trial MA.12 (N = 672), patients with higher baseline BMI had worse BCFI (P = 0.02) after 1 year, worse DSS (P = 0.05; 0.004) after 1 and 5 years and worse OS (P = 0.01) after 5 years. Increased BMI did not impact BCFI (P = 0.90) after 5 years, although it was associated with worse BCFI (P = 0.01) after 1 year. In post-menopausal endocrine therapy trials MA.14 and MA.27 (N = 8236), baseline BMI did not significantly impact outcome for any endpoint. BMI change did not impact BCFI or DSS after 1 or 3 years, although a mean increased BMI of 0.3 was associated with better OS (P = 0.02) after 1 year. With the administration of trastuzumab (N = 1395) baseline BMI and BMI change did not significantly impact outcomes.

Conclusions: Higher baseline BMI and BMI increases negatively affected outcomes only in pre-/peri-/early post-menopausal trial patients. Otherwise, BMI increases similar to those expected in healthy women either did not impact outcome or were associated with better outcomes.

Clinical trials numbers: CAN-NCIC-MA5; National Cancer Institute (NCI)-V90-0027; MA.12-NCT00002542; MA.14-NCT00002864; MA.21-NCT00014222; HERA, NCT00045032;CAN-NCIC-MA24; MA-27-NCT00066573.

Keywords: BMI; disease specific survival; overall survival; triple negative; weight change.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
CONSORT diagram: patients in phase III adjuvant trials, classified by menopausal status and type of trial systemic therapy. CEF is cyclophosphamide, epirubicin, fluorouracil; CMF is cyclophosphamide, methotrexate, fluorouracil; AC is doxorubicin, cyclophosphamide; EC/T is epirubicin, cyclophosphamide followed by paclitaxel; AC/T is doxorubicin, cyclophosphamide followed by paclitaxel.
Figure 2.
Figure 2.
Effects of baseline BMI and BMI change on breast cancer free interval (BCFI), disease specific survival (DSS), overall survival (OS): Pre-, peri-, and early post-menopausal adjuvant chemotherapy trials. SE is standard error; HR is hazard ratio; LCL is the lower 95% confidence limit; UCL is the upper 95% confidence limit; P-value is based on a two-sided Wald statistic from a stratified Cox model.
Figure 3A.
Figure 3A.
Effects of baseline BMI and BMI change on breast cancer free interval (BCFI), disease specific survival (DSS), overall survival (OS): Pre- and peri-menopausal adjuvant endocrine therapy. SE is standard error; HR is hazard ratio; LCL is the lower 95% confidence limit; UCL is the upper 95% confidence limit; P-value is based on a two-sided Wald statistic from a stratified Cox model.
Figure 3B.
Figure 3B.
Effects of baseline BMI and BMI change on breast cancer free interval (BCFI), disease specific survival (DSS), and overall survival (OS): Triple negative patients. SE is standard error; HR is hazard ratio; LCL is the lower 95% confidence limit; UCL is the upper 95% confidence limit; P-value is based on a two-sided Wald statistic from a stratified Cox model.
Figure 4.
Figure 4.
Effects of baseline BMI and BMI change on breast cancer free interval (BCFI), disease specific survival (DSS), overall survival (OS): Post-menopausal adjuvant endocrine therapy. SE is standard error; HR is hazard ratio; LCL is the lower 95% confidence limit; UCL is the upper 95% confidence limit; P-value is based on a two-sided Wald statistic from a stratified Cox model. *indicates Cox model not fit due to lack of events.
See this image and copyright information in PMC

References

    1. Ligibel JA, Alfano CM, Kerry S. et al. American Society of Clinical Oncology Position Statement on Obesity and Cancer. J Clin Oncol 2014; 31: 3568–3574. - PMC - PubMed
    1. Rock CL, Doyle C, Demark-Wahnefried W. et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012; 62: 243–274. - PubMed
    1. Kushi LH, Doyle C, McCullough M. et al. American cancer society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2012; 62: 30–67. - PubMed
    1. Schmitz KH, Courneya KS, Matthews C. et al. American college of sports medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010; 42: 1409–1426. - PubMed
    1. National Comprehensive Cancer Network: NCCN guidelines for supportive care, survivorship. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive (27 February 2015, date last accessed).

MeSH terms

Substances

Associated data